Hypnotics use in children 0–18 months: moderate agreement between mother-reported survey data and prescription registry data

Table 2 Agreement between at least one-time mother reported use of hypnotics and at least one dispensed prescription for a hypnotic drug to children aged 0–18 months

	Maternal report (MoBa)			Dispensed drugs (NorPD)			Neither	Only MoBa	Only NorPD	Both		Agreement^d
Drug category (ATC code)	n	%	95% CI	n	%	95% CI	n	n	n	n	total
Alimemazine (R06AD01)	367	0.78%	0.70–0.86%	745	1.58%	1.47–1.69%	46,459	106	484	261	47,310	46.3
Promethazine (R06AD02)	14	0.03%	0.02–0.05%	0			47,297	14	0	0	47,310	0
Dexchlorpheniramine (R06AB02)	1131	2.39%	2.26–2.53%	2101	4.44%	4.26–4.64%	44,811	398	1368	733	47,310	43.6
Hypnotics and sedatives (N05C)^a	39	0.08%	0.06–0.11%	38	0.08%	0.06–0.11%	47,249	23	22	16	47,310	41.0
Anxiolytics (N05B)^b	62	0.14%	0.11–0.17%	351	0.74%	0.67–0.82%	46,935	24	311	40	47,310	19.1
Recommended antiepileptic’s (from ATC N03A)^c	49	0.10%	0.08–0.14%	50	0.11%	0.08–0.14%	47,257	3	4	46	47,310	92.9

^aincludes nitrazepam, midazolam and melatonin
^bincludes diazepam, clobazam and hydroxyzine
^cFirst choice drugs for treatment of childhood epilepsy. Includes carbamazepine N03AF01, oxcarbazepine N03AF02, lamotrigine N03AX09, topiramat N03AX11, and valproate N03AG01. Recommended by the Norwegian Society of Paediatricians
^dCalculated using Cohen’s Kappa

ISSN: 2052-3211